Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06412471
PHASE2
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
View on ClinicalTrials.gov
Summary
This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
235
Start Date
2024-07-26
Completion Date
2025-08
Last Updated
2024-07-30
Healthy Volunteers
No
Conditions
Interventions
DRUG
SSGJ-707
bispecific antibody
DRUG
carboplatin
chemotherapy
DRUG
Pemetrexed
chemotherapy
DRUG
paclitaxel
chemotherapy
DRUG
PD-1/L1
Immune checkpoint inhibitors
DRUG
Paclitaxel-albumin
chemotherapy
Locations (1)
Institute of The Hunan Cancer Hospital
Changsha, China